Myeloproliferative disorders (MPDs) result from the abnormal proliferation of myeloid precursor cells in the bone marrow. Understanding the genetic events which result in MPDs will not only improve our understanding of the disease process, but will also provide insights into the normal developmental control in early progenitor cells. A variant form of this disease is associated with T-cell leukemia/lymphoma and peripheral blood eosinophilia. The clinical course of the disease is particularly aggressive with rapid progression of the disease to acute myelogenous leukemia or stem cell leukemia. The involvement of both myeloid and T-cell lineages in this disease strongly suggest a primitive origin for the cells involved, before the commitment to a particular lineage. These tumors invariably show a highly specific, reciprocal chromosome translocation involving chromosomes 8 and 13. This specific translocation is always involved with this biphenotypic tumor indicating that genes located at the translocation breakpoints play an important role in disease development. The genes involved in this rearrangement have now been identified as FGFR1 in chromosome region 8p11 and a zinc finger gene, ZNF198, of unknown function, in 13q12. The molecular conequences of this rerrangement have been shown to be identical in all of the four cases we have analyzed. As a result of the rearrangement a fusion gene is generated which is under the control of the ZNF198 promoter. This novel gene carries the zinc finger motif of ZNF198 fused to the tyrosine kinase domain of FGFR1. Because of the highly specific nature of this rearrangement and its consistent presence in all of the tumors analyzed to date, this rearrangement must clearly be important in leukemogenesis in these patients. Our goals therefore are (1) to transform normal cells using the fusion gene in order to establish a functional assay in vitro, (2) to create a transgenic mouse line expressing the fusion protein and so establish an in vivo model to study the biological consequences of the translocation and (3) since the fusion gene may act as a dominant-negative we will also investigate the normal function of ZNF198 in order to compare its activity with that of the fusion gene. As a result of our improved understanding of the genetic events which give rise to this MPD, it may eventually be possible to design novel therapeutic approaches to this disease directed against the aberrant gene(s) and its product.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA076167-01A2
Application #
2841581
Study Section
Pathology B Study Section (PTHB)
Program Officer
Shen, Grace L
Project Start
1999-04-01
Project End
2004-01-31
Budget Start
1999-04-01
Budget End
2000-01-31
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Cleveland Clinic Lerner
Department
Type
DUNS #
017730458
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Hu, Tianxiang; Chong, Yating; Qin, Haiyan et al. (2018) The miR-17/92 cluster is involved in the molecular etiology of the SCLL syndrome driven by the BCR-FGFR1 chimeric kinase. Oncogene 37:1926-1938
Hu, Tianxiang; Wu, Qing; Chong, Yating et al. (2018) FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome. Leukemia :
Hu, Tianxiang; Chong, Yating; Lu, Sumin et al. (2018) miR-339 Promotes Development of Stem Cell Leukemia/Lymphoma Syndrome via Downregulation of the BCL2L11 and BAX Proapoptotic Genes. Cancer Res 78:3522-3531
Cowell, John K; Qin, Haiyan; Hu, Tianxiang et al. (2017) Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas. Int J Cancer 141:1822-1829
Wu, Qing; Bhole, Aaron; Qin, Haiyan et al. (2016) SCLLTargeting FGFR1 to suppress leukemogenesis in syndromic and de novo AML in murine models. Oncotarget 7:49733-49742
Cowell, John K; Qin, Haiyan; Chang, Chang-Sheng et al. (2016) A model of BCR-FGFR1 driven human AML in immunocompromised mice. Br J Haematol 175:542-545
Qin, H; Malek, S; Cowell, J K et al. (2016) Transformation of human CD34+ hematopoietic progenitor cells with DEK-NUP214 induces AML in an immunocompromised mouse model. Oncogene 35:5686-5691
Ren, Mingqiang; Qin, Haiyan; Wu, Qing et al. (2016) Development of ZMYM2-FGFR1 driven AML in human CD34+ cells in immunocompromised mice. Int J Cancer 139:836-40
Qin, Haiyan; Wu, Qing; Cowell, John K et al. (2016) FGFR1OP2-FGFR1 induced myeloid leukemia and T-cell lymphoma in a mouse model. Haematologica 101:e91-4
Ren, Mingqiang; Qin, Haiyan; Kitamura, Eiko et al. (2013) Dysregulated signaling pathways in the development of CNTRL-FGFR1-induced myeloid and lymphoid malignancies associated with FGFR1 in human and mouse models. Blood 122:1007-16

Showing the most recent 10 out of 24 publications